GSK’s Horlicks Review Plan - Some Early Expectations In India

A potential sale of Horlicks could impact market dynamics significantly in India where the popular malt beverage holds a dominant position but has seen competition build up. GlaxoSmithKline, though, has underscored that the review plan had nothing to do with the product’s "critical mass".

Leadership
A POTENTIAL SALE OF HORLICKS COULD IMPACT MARKET DYNAMICS IN INDIA

GlaxoSmithKline PLC’s decision to potentially divest the popular malted milk drink Horlicks, which is largely sold through its publicly listed Indian subsidiary,GlaxoSmithKline Consumer Healthcare, isn’t about market-related pressures, the UK multinational’s top brass has emphasized.

“I want to be absolutely clear that this has, for a long time, been a winning and performing brand, primarily...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip